Skip to main navigation Skip to search Skip to main content

2024 update on postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia

  • Maciej Banach*
  • , Niki Katsiki
  • , Gustavs Latkovskis
  • , Dan Gaita
  • , Carlos Escobar
  • , Daniel Pella
  • , Peter E. Penson
  • , Federica Fogacci
  • , Zeljko Reiner
  • , Arrigo F.G. Cicero
  • *Corresponding author for this work
  • Medical University of Łódź
  • Institute of Polish Mother's Health Center
  • University of Zielona Gora
  • International Hellenic University
  • European University Cyprus
  • Paula Stradina Clinical University Hospital
  • Victor Babes University of Medicine and Pharmacy
  • Institutul de Boli Cardiovasculare
  • Hospital Universitario La Paz
  • Pavol Jozef Šafárik University
  • Liverpool John Moores University
  • Liverpool Centre for Cardiovascular Science
  • University of Bologna

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Introduction: Considering lack of a European standardized postmarketing food supplement surveillance system (nutrivigilance), some member states and companies have developed their own approaches to monitoring potential adverse reactions (AEs) to secure a high level of product safety. This paper updates 2021 results of the use of a nutrivigilance system (which contained data to the end of 2019) in monitoring the incidence of spontaneously reported suspected AEs associated with red yeast rice (RYR) containing food supplements. Material and methods: We report the data from a widely used product marketed under the trademark Armolipid/Armolipid Plus. Postmarketing information was collected in a voluntary nutrivigilance system established by the manufacturing company (Meda Pharma SpA, a Viatris Company, Monza, Italy). From 1st October 2004 to 31st December 2023, this system captured cases of suspected adverse reactions spontaneously reported by consumers, healthcare professionals, health authorities, regardless of causality. Results: The total number of case reports received mentioning the RYR food supplement product line increased to 1186, in which 1904 adverse events (AEs) were reported. The total reporting rate of AEs was estimated to be 0.049% of 3,880,865 exposed consumers. Of the 1186 cases, 28 (0.0007% of exposed consumers) included suspected serious adverse events (SAEs). After very careful investigation, 9 cases (0.0002% of consumers exposed) and 12 AEs were assessed by the manufacturer as serious and potentially related to exposure to the above-mentioned RYR-based nutraceutical. Off-label reports linked to the newly introduced limitation at 70 years of age were observed, in contrast to the previous analysis. Conclusions: This updated nutrivigilance-derived data analysis confirms a very low incidence of suspected AEs associated with the RYR product line. Consumer safety of food supplements could be generally improved by raising awareness of the importance of following the indications and warnings detailed in a food supplement’s labelling. Changes to the exposed population may impact the reporting rates.

Original languageEnglish
Pages (from-to)729-737
Number of pages9
JournalArchives of Medical Science
Volume21
Issue number3
DOIs
Publication statusPublished - 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 9 - Industry, Innovation, and Infrastructure
    SDG 9 Industry, Innovation, and Infrastructure

OECD Field of Science

  • 3.1 Basic Medicine

Keywords

  • adverse events
  • dyslipidaemia
  • food supplements
  • nutrivigilance
  • red yeast rice

Fingerprint

Dive into the research topics of '2024 update on postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia'. Together they form a unique fingerprint.

Cite this